A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate

• Status: Completed
• Trial end date: 2021-04-22
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to collect follow-up safety data from participants in completed abiraterone acetate studies for a maximum duration of 6 years.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Janssen Research & Development, LLC
• Treatments: Abiraterone Acetate; Prednisone

Criteria

Inclusion Criteria:

• Currently participating in an abiraterone acetate clinical study considered complete and had received at least 3 months of treatment with abiraterone acetate tablets.

Exclusion Criteria:

• Medical conditions that require hospitalization.

• Any condition or situation which, in the opinion of the investigator, may put the patient at significant risk, may confound the study results, or may interfere significantly with the patient's participation in the study.